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FibrosisDupuytren's disease (DD) is a common and heritable ﬁbrosis of the palmar fascia that typically manifests as
permanent ﬁnger contractures. The molecular interactions that induce the development of hyper-contractile
ﬁbroblasts, or myoﬁbroblasts, in DD are poorly understood. We have identiﬁed IGF2 and IGFBP6, encoding
insulin-like growth factor (IGF)-II and IGF binding protein (IGFBP)-6 respectively, as reciprocally dys-
regulated genes and proteins in primary cells derived from contracture tissues (DD cells). Recombinant
IGFBP-6 inhibited the proliferation of DD cells, patient-matched control (PF) cells and normal palmar fascia
(CT) cells. Co-treatments with IGF-II, a high afﬁnity IGFBP-6 ligand, were unable to rescue these effects. A
non-IGF-II binding analog of IGFBP-6 also inhibited cellular proliferation, implicating IGF-II-independent
roles for IGFBP-6 in this process. IGF-II enhanced the proliferation of CT cells, but not DD or PF cells, and sig-
niﬁcantly enhanced DD and PF cell contractility in stressed collagen lattices. While IGFBP-6 treatment did not
affect cellular contractility, it abrogated the IGF-II-induced contractility of DD and PF cells in stressed collagen
lattices. IGF-II also signiﬁcantly increased the contraction of DD cells in relaxed lattices, however this effect
was not evident in relaxed collagen lattices containing PF cells. The disparate effects of IGF-II on DD and PF
cells in relaxed and stressed contraction models suggest that IGF-II can enhance lattice contractility through
more than one mechanism. This is the ﬁrst report to implicate IGFBP-6 as a suppressor of cellular prolifera-
tion and IGF-II as an inducer of cellular contractility in this connective tissue disease.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Dupuytren's disease (DD) is a debilitating condition of the hand
[1,2] characterized by the formation of collagenous cords in the pal-
mar and/or digital fascia and permanent ﬁnger contractures. Despite
being amongst the most common inherited connective tissue diseases
[1–4], the etiopathology of DD has remained elusive since its descrip-
tion in the 1830s [5]. While microsurgical excision [6] of the contrac-
tile cord tissue can temporarily restore dexterity, this and otherearch Institute, 268 Grosvenor
Tel.: +1 519 646 6100x64397,
, jcrawfo9@uwo.ca
nash.edu (P. Fu),
(D.B. O'Gorman).
.V. Open access under CC BY license.treatment approaches fail to prevent disease recurrence in more
than 30% of patients [7–10]. There is a clear need for a better under-
standing of the molecular pathology of DD to achieve more effective
therapeutic approaches.
Due to the unique physiology of the palmar fascia and the lack of
understanding of DD at a molecular level, there are no established an-
imal or immortalized cell models in which to study DD development.
We take the approach of comparing primary ﬁbroblasts derived from
surgically resected DD contracture (cord) tissue (DD cells) to ﬁbro-
blasts derived from the palmar fascia of the adjacent, phenotypically
unaffected digit exposed during surgery (PF cells). While DD may
be associated with increased cancer mortality in some populations
[11,12], patients with a family history of ﬁnger contractures do not
display any major chromosomal rearrangements or deletions [13]
and DD is considered a benign, heritable ﬁbrosis [4]. Single nucleotide
polymorphisms (SNPs) have been identiﬁed as potential markers of
this heritability [14], and these polymorphisms are predicted to be
present in all somatic tissues in these patients rather than limited to
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matched “latent disease” cells that carry the same predisposing SNPs
as DD cells, making them the ideal controls for studies of themolecular
mechanisms that promote disease development in this population. In
addition, we derive a second control group of palmar fascia ﬁbroblasts
(CT cells) frompatientswith no history of DDwho are undergoing sur-
geries for unrelated reasons, such as carpal tunnel release. We consid-
er CT cells to be normal controls and useful comparators to patient
matched PF/DD cells in studies designed to identify characteristics
that are speciﬁc to cells predisposed to DD development [15,16].
Using these unique cellmodels,we have focused on identifyingmol-
ecules that regulate the proliferation and differentiation of palmar fascia
ﬁbroblasts into myoﬁbroblasts, the hyper-contractile cell type that
remodels the palmar fascia to induce ﬁnger contractures in DD. Several
research groups have previously reported gene expression analyses of
DD tissues or cells with the aim of identifying dysregulated genes
with potential roles inmyoﬁbroblast development [13,16–20]. Our pre-
vious studies have focused on TGFB1, encoding transforming growth
factor-β1 (TGF-β1) and TGF-β-induced genes such as periostin [21]. In
parallel, we and others [19] have identiﬁed IGFBP6 as a signiﬁcantly
downregulated transcript in DD tissue. The relevance of downregulated
IGFBP6 expression to the proliferation and differentiation of palmar fas-
cia ﬁbroblasts into DDmyoﬁbroblasts has not been previously explored.
IGFBP6 encodes insulin-like growth factor binding protein (IGFBP)-6,
one of a family of six secreted proteins that bind insulin-like growth
factors (IGFs)-I and -II with high afﬁnity and regulate their bio-
availability [22]. While most IGFBPs can regulate the availability of
both IGF-I and IGF-II under normal physiological conditions,
IGFBP-6 is unique in displaying a 50 fold higher afﬁnity for IGF-II
[23,24], identifying it as an IGF-II-speciﬁc binding protein under nor-
mal physiological conditions [23].
In this study, we demonstrate that IGFBP6mRNA and IGFBP-6 pro-
tein levels are downregulated components of DD cells, and that IGF2
mRNA and IGF-II peptide levels are upregulated in DD cells relative
to controls. Recombinant IGFBP-6 was found to inhibit the prolifera-
tion of DD, PF and CT cells, and co-treatment with IGF-II was mostly
ineffective at neutralizing these effects. IGF-II signiﬁcantly enhanced
DD cell contractility and this effect could be abrogated by IGFBP-6.
Overall, these ﬁndings implicate IGFBP-6 and IGF-II as previously
unrecognized regulators of DD cell proliferation and contractility that
may have potential as therapeutic targets in this and related ﬁbro-
contractile diseases.
2. Methods
2.1. Clinical specimen collection
Surgically resected Dupuytren's disease cords were collected from
patients undergoing primary surgical resections at St Joseph's Hospi-
tal, London, Ontario. Samples of phenotypically normal palmar fascia
tissue exposed during surgery were collected from an adjacent, visu-
ally unaffected digit for comparative analyses. None of these patients
were being treated for recurrent disease. In addition, small samples of
palmar fascia were collected from patients without Dupuytren's dis-
ease who are undergoing hand surgery for unrelated reasons, such
as carpal tunnel release, in which the palmar fascia was phenotypical-
ly unaffected. All subjects provided written informed consent and
specimens were collected with the approval of the University of
Western Ontario Research Ethics Board for Health Sciences Research
involving Human Subjects (HSREB protocol # 08222E).
2.2. Immunohistochemistry
Surgically resectedDDcord andpatientmatched, phenotypically nor-
mal palmar fascia samples were ﬁxed in 10% formalin prior to dehydra-
tion, parafﬁn embedding and microtome sectioning. Parafﬁn-embeddedspecimens were sectioned (5 μm), dewaxed, rehydrated and treated
with a 3% hydrogen peroxide solution to quench endogenous peroxi-
dase activity. Slides were treated with a serum-free blocking reagent
(Background Sniper, Biocare Medical, Concord, CA) for 10 min and
rinsed in PBS prior to incubationwith rabbit polyclonal IGFBP-6 (Austral
Biologicals, San Ramon, CA) overnight at 4 °C. After a wash in PBS, the
slides were incubated (30 min, 22 °C) with a biotinylated secondary
anti-rabbit antibody (Vector Labs, Burlington ON), washed brieﬂy in
PBS, and incubated (30 min, 22 °C) with avidin/biotin/HRP complex
(Vector elite PK-6100, Vector Labs, Burlington ON). Finally, the slides
were washed with PBS, and incubated (1 min) in an enhanced
diaminobenzidine (CardassianDAB; BiocareMedical, Concord, CA). Sec-
tions were counterstained with methyl green (10 min), dehydrated,
cleared, and mounted with Permount (Fisher Scientiﬁc, Ottawa, ON).
2.3. Primary cell culture
Primary ﬁbroblasts were isolated from surgically resected DD cord
tissues (DD cells), phenotypically normal (non-ﬁbrotic) palmar fascia
tissue from an adjacent, visually unaffected digit (PF cells) and nor-
mal palmar fascia (CT cells) as previously described [25]. The cultures
were maintained in α-MEM-medium supplemented with 10% fetal
bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA) and 1% an-
tibiotic–antimycotic solution (Sigma-Aldrich, St. Louis, MO). All pri-
mary cell lines (DD, PF and CT cells) were assessed at the lowest
passage number achievable up to a maximum of 6 passages, after
which the cells were discarded. No changes in cell morphology,
growth/viability or contractility attributable to serial passage were
evident in these cells.
2.4. Real time PCR
Total RNA samples from primary DD, PF and CT cells were assessed
for quality on an Agilent 2100 Bioanalyzer. 2 μg of high quality total
RNA was reverse transcribed into cDNA ﬁrst strand using the High-
Capacity cDNA Archive Kit (Applied Biosystems) in accordance with
the manufacturer's instructions. TaqMan gene expression assays
were used to measure IGFBP6, IGF2 and IGF1 expressions. IGFBP6
(Hs00181853_m1) and IGF2 (Hs01005963_m1) expressions were
measured relative to the RPLP0 endogenous control (Hs99999902_m1),
and IGF1 (Hs01547656_m1) was measured relative to GAPDH
(Hs99999905_m1) using the ΔΔCt method after conﬁrmation of par-
allel PCR ampliﬁcation efﬁciencies on a Real-Time PCR ABI Prism 7500.
PCR reactions were carried out under the following conditions: Initial
denaturation at 95 °C for 5 min followed by cycles of denaturation
(95 °C for 15 s), primer annealing (60 °C for 1 min) and transcript
extension (50 °C for 2 min) for 45 cycles.
2.5. Western immunoblotting
Surgically resected tissues were snap-frozen in liquid nitrogen and
protein extracts were prepared using a tissue bio-pulverizer and
PhosphoSafe Protein Extraction Buffer (VWR, Mississauga, ON). Cul-
tured cells were lysed in RIPA Cell Lysis Buffer (Teknova Inc., Hollister,
CA) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St.
Louis,MO), 0.1 MNaF, 10 mMPMSF and 10 mMsodiumorthovanadate
and placed on ice for 30 min after needle aspiration. After centrifuga-
tion to remove insolublematerial, total protein concentrationswere de-
termined by BCA analysis. 15% PAGE and Western immunoblotting
were performed using standard procedures and proteins were visual-
ized using enhanced chemiluminescence (ECL). The primary antibodies
utilized were mouse monoclonal IGF-II (Upstate Biotechnology, Etobi-
coke, ON) and mouse monoclonal β-actin (Santa Cruz Biotechnology,
Dallas, TX). Total protein (albumin) levels were assessed by Ponceau S
staining (Sigma Aldrich, Oakville, ON, Canada).
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The levels of secreted IGFBP-6 in DD and PF cell conditionedmedia
were assessed using the Luminex xMAP ﬂuorescent bead-based tech-
nology (Luminex Corporation, Austin, TX) and the Bio-Plex 200 read-
out system according to the manufacturer's instructions (Bio-Rad
Laboratories Inc., Hercules, CA). IGFBP-6 levels were calculated from
standard curves of recombinant IGFBP-6 in a solution using Bio-Plex
Manager software (v.4.1.1, Bio-Rad).
2.7. WST-1 cell proliferation assay
TheWST-1 assay (Millipore/Chemicon, Billerica,MA)was adapted to
measure changes in the proliferation of primary ﬁbroblasts grown on
type-1 collagen, themost abundant protein component of palmar fascia.
We have included type-1 collagen substrates in all our assays to more
closely replicate in vivo conditions. In brief, 2 × 103 cells were plated
in α-MEM/2% FBS in 4 × 96 well trays pre-coated with 60 μl of type-1
collagen (1.8 mg/ml), treatments or vehicles were added, and the
trays were incubated at 37 °C for 7 days. WST-1 reagent was added to
the wells on days 1, 3, 5 and 7 to allow cleavage of the tetrazolium salt
to formazan by cellular mitochondrial dehydrogenases. Equal volumes
of supernatant were transferred to additional 96 well trays and absor-
bance measurements were performed at 450 nm and 650 nm (refer-
ence wavelength). This assay measures total cellular mitochondrial
activity andwe have demonstrated a linear correlation betweenmanual
cell counts and WST-1 absorbance values over a range of 0.1 to 0.4 ab-
sorbance units at 450 nm for cells grown on type-1 collagen substrates
(data not shown). We interpret these outputs as net proliferation
(total cell number changes due to the combined effects of mitogenesis
and apoptosis). All experiments were performed at least three times
on a minimum of 4 DD, PF and CT cell lines, each assessed in triplicate.
2.8. Fibroblast populated collagen lattice assays
Collagen contraction assays were carried out using modiﬁed ver-
sions of Bell et al. [26] and Tomasek and Rayan [27]. In brief, the contrac-
tility of DD, PF and CT cells at low passage (≤6) was assessed in
three-dimensional ﬁbroblast populated collagen lattices (FPCLs). Colla-
gen lattices were cast in 24-well tissue culture trays with each well
containing 400 μl collagen (ﬁnal collagen concentration of 1.8 mg/ml),
100 μl neutralization solution, treatment or vehicle, and 1 × 105 cells.
FPCLs were maintained in α-MEM supplemented with 2% FBS and 1%
antibiotic–antimycotic solution at 37 °C in 5% CO2. For “relaxed” FPCLs
(rFPCLs), lattices were allowed to polymerize for 1 h before being gent-
ly released from the sides and bottoms of the wells using a metal rod.
Relaxed FPCLs typically undergo gradual lattice contraction over 24 h
in tissue culture media. Floating lattices for rFPCLs were digitally
scanned at 24.0 h only. For “stressed” FPCLs (sFPCLs), the collagen lat-
tices remained attached to thewells for 72 h to allow the cells to induce
(and respond to) stress within the lattice and differentiate toward a
contractile myoﬁbroblast phenotype [28]. Lattices were released after
72 h, typically resulting in rapid contraction over 6 h. Floating lattices
for sFPCLs were digitally scanned at release (0 h), 0.5 h, 1.0 h, 2.0 h
and 6.0 h. The areas of individual lattices in rFPCLs and sFPCLs were de-
termined using the freehand tool in ImageJ software. Sequential area
calculations were then normalized to the area of the lattice (i.e. the
area of thewell in which the lattice was cast) prior to release. All exper-
iments were performed on a minimum of 3 and a maximum of 10 DD,
PF and CT cell lines, each assessed in 3 separate experiments, in
triplicate.
2.9. Statistical analyses
Statistical analysis was conducted using SPSS v. 17 and Microsoft
Excel 2007 statistical software. For sFPCL data, repeated measuresanalysis of variance analyses were used to assess the signiﬁcance of
treatment effects and treatment/time interactions to distinguish
overall treatment-induced changes in contractility from treatment-
induced changes in contractility that became signiﬁcant over time.
Signiﬁcant treatment/time interactions were further assessed with
simple main effects analyses to determine at which time point a treat-
ment had a signiﬁcant effect. Paired t-tests were used to determine
signiﬁcant changes in contractility at 24 h in rFPCLs and in prolifera-
tion by change score analysis between day 7 and day 1. Results were
deemed signiﬁcant when p b 0.05.
3. Results
3.1. IGFBP6 mRNA and IGFBP-6 levels are attenuated in Dupuytren's
disease tissues and in DD cells
While IGFBP6 has been identiﬁed as a signiﬁcantly downregulated
gene transcript in gene array studies comparing DD tissues to pheno-
typically unaffected palmar fascia [19,21], corresponding changes in
IGFBP-6 levels have not been reported. As shown in Fig. 1A, a corre-
sponding decrease in IGFBP-6 immunoreactivity was evident in
parafﬁn-embedded sections of DD cord relative to visibly unaffected
palmar fascia tissue from an adjacent digit in the same patients
(Fig. 1B). This decrease in IGFBP-6 immunoreactivity in DD tissue
was despite an inverse disparity in the number of palmar fascia cells
(stained with methyl green in Fig. 1A and B) in DD cord tissues and
the adjacent palmar fascia. To conﬁrm the cellular source of IGFBP-6
in DD tissues, we assessed IGFBP6 expression in primary ﬁbroblasts
derived from diseased palmar fascia (DD cells) relative to primary
ﬁbroblasts derived from the adjacent, phenotypically unaffected
palmar fascia of the same patients (PF cells). As shown in Fig. 1C,
IGFBP6 mRNA levels were signiﬁcantly lower in DD cells than in
genetically matched PF cells. We also assessed IGFBP-6 secretion in
DD and PF cells, and compared them to primary ﬁbroblasts derived
from normal palmar fascia from unrelated patients undergoing treat-
ment for unrelated conditions (CT cells). IGFBP-6 secretion was sig-
niﬁcantly reduced in DD cells relative to PF cells and CT cells over
48 h when cultured under identical serum free conditions (Fig. 1D).
3.2. IGF2 mRNA and IGF-II levels are increased in DD cells
As IGFBP-6 has been reported to elicit effects by sequestering
IGF-II, we assessed basal IGF2 expression in DD and PF cells. IGF2
mRNA levels were consistently (n = 6 patients) and signiﬁcantly
(p b 0.05) increased in DD cells relative to patient-matched PF cell
controls and non-patient-matched CT cells (Fig. 2A). In contrast to
IGF2, the expression of IGF1, encoding insulin-like growth factor-I,
was unchanged between DD and PF cells (Fig. 2B). To determine if
increased IGF2 expression resulted in increased IGF-II secretion, we
assessed IGF-II levels in DD cord tissue and DD cell lysates. As
shown in Fig. 2C, IGF-II immunoreactivity was increased in DD tissue
and cell lysates relative to normal palmar fascia tissue and PF cell
lysates. Multiple bands correlating with precursor forms of IGF-II, in-
cluding “big” IGF-II and variably glycosylated pro-IGF-II previously
reported in human serum [29] were evident in all cell lysates. As
our ﬁndings indicated reciprocal changes in IGFBP6 and IGF2 mRNA
levels and IGFBP-6 and IGF-II protein levels in DD cells relative to con-
trols, we compared the effects of recombinant IGFBP-6 and recombi-
nant IGF-II, individually and in combination, on the net proliferation
and contractility of DD and PF cells.
3.3. IGFBP-6 inhibits DD cell proliferation in an IGF-II
independent manner
Based on our analyses of IGFBP-6 secretion by CT cells (Fig. 1D)
and previous studies in tumor cells [30], we chose to assess the effects
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Fig. 1. IGFBP6 expression and IGFBP-6 secretion are downregulated in Dupuytren's disease (DD). Sections of parafﬁn embedded DD “cord” tissue (A) and adjacent, phenotypically
unaffected palmar fascia tissue (B) were assessed for IGFBP-6 immunoreactivity, evident as brown (diaminobenzidine, DAB) staining. Palmar fascia ﬁbroblasts were counter-stained
with methyl green. C) QPCR analysis of IGFBP6 mRNA levels in primary ﬁbroblasts derived from phenotypically unaffected palmar fascia (PF cells) and DD cord tissue (DD cells)
from the same patients (* = p b 0.05 for DD vs PF samples, N = 3). D) IGFBP-6 secretion by normal palmar fascia ﬁbroblasts (CT cells), PF cells and DD cells in serum free
media over 48 h (* = p b 0.05 for DD vs CT samples, N = 3).
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shown in Fig. 3A, a single treatment with 400 ng/ml of recombinant
IGFBP-6 on day 0 induced a signiﬁcant reduction in DD (p b 0.01), PF
and CT (each p b 0.05) cell proliferation over the subsequent 7 days rel-
ative to vehicle treated cells.While a single treatmentwith recombinant
IGF-II at 100 ng/ml signiﬁcantly enhanced CT cell proliferation over
7 days (p b 0.05), no signiﬁcant effects of IGF-II treatment on the prolif-
eration of DD or PF cells were detected (Fig. 3B).
As shown in Fig. 3C, co-incubation of cells with IGFBP-6 and IGF-II
at equimolar concentrations did not rescue the inhibitory effects of
IGFBP-6 treatment. To conﬁrm IGF-II independence of these effects
on cell proliferation, DD, PF and CT cells were treated with a single
dose of a non-IGF-II binding IGFBP-6 analog (mIGFBP-6) [31] at
400 ng/ml. IGFBP-6 and mIGFBP-6 had similar inhibitory effects on
the proliferation of PF cells (p b 0.05, Fig. 3D) and CT cells (p b 0.01,
data not shown). Unlike in PF and CT cells, mIGFBP-6 was signiﬁcant-
ly (p b 0.05) less effective at inhibiting DD cell proliferation than
IGFBP-6, although both treatments had statistically signiﬁcant nega-
tive effects relative to vehicle treated cells (p b 0.01).
3.4. IGF-II enhances DD cell contraction of collagen lattices
To assess the effects of IGF-II and IGFBP-6 on DD and PF cell con-
tractility, we utilized two types of ﬁbroblast populated collagen lat-
tice assays, relaxed FPCLs (rFPCLs) [28,32–34] and stressed FPCLs
(sFPCLs) [21,35,36]. The 72 h incubation period in the presence oftreatments in the sFPCL protocol allowed us to distinguish the effects
of treatment-induced myoﬁbroblast differentiation [37] from the im-
mediate effects of treatment that are measured in rFPCLs [33].
DD cells were more contractile than PF cells in rFPCL assays in the
absence of treatment (Fig. 4A). IGFBP-6 (400 ng/ml) did not signiﬁ-
cantly affect the contractility of DD, PF or CT cells in rFPCLs (data
not shown). IGF-II (100 ng/ml) signiﬁcantly enhanced rFPCL contrac-
tion by DD cells (p b 0.05) but did not signiﬁcantly affect PF or CT cell
contractility (Fig. 4A). Platelet derived growth factor (PDGF), an
established inducer of ﬁbroblast contractility in rFPCLs [33], enhanced
both DD and PF cell contractility in these assays.
IGFBP-6 (400 ng/ml) did not signiﬁcantly affect the contractility of
DD, PF or CT cells in sFPCLs (data not shown). IGF-II treatment signif-
icantly enhanced both PF (p b 0.05) and DD (p b 0.001) cell contrac-
tility over 6 h after lattice release (Fig. 4C and D respectively). In
addition to treatment effects, signiﬁcant IGF-II treatment/time inter-
actions were evident for both cell types (p b 0.01). While IGF-II
signiﬁcantly induced DD cell contraction at all time points after re-
lease, the level of signiﬁcance increased from p b 0.01 at release to
p b 0.001 6 h after release. Signiﬁcant effects of IGF-II treatment
were only evident 2 h after release in PF cells (p b 0.05). TGF-β1
treatment (12.5 ng/ml) signiﬁcantly enhanced DD cell (p b 0.01)
contractility in these assays, whereas a signiﬁcant TGF-β1 treatment/
time interaction was evident in PF cells (p b 0.01) 6 h after lattice
release (p b 0.01) (Fig. 4B). IGF-II did not signiﬁcantly affect sFPCL con-
traction by CT cells (data not shown). Co-treatments with equimolar
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and PF cells (Fig. 5A).
As TGF-β1 signaling intermediates and IGF-II have been reported
to elicit combinatorial effects on myoﬁbroblast differentiation in mu-
rine ﬁbroblasts [38], we assessed the effects of treating PF and DD
cells with both growth factors in combination (Fig. 5B). While
TGF-β1 and IGF-II treatments signiﬁcantly enhanced the contractility
of PF and DD cells relative to vehicle treated controls, no combinato-
rial treatment effects were detected over treatment with either factor
in isolation.
4. Discussion
In this study, we have identiﬁed IGFBP6 and IGF2 as reciprocally
dysregulated genes in DD cells relative to PF cells. Previous studies
have reported the increased TGF-β1 expression and sensitivity, en-
hanced contractility, α smooth muscle actin (αSMA) expression and
myoﬁbroblast differentiation in DD cells [39–41], features shared
with primary myoﬁbroblast-like cells derived from other ﬁbroses
[42–44]. Other than TGF-β1, very few of the dysregulated genes in
DD cells have been functionally linked to the main characteristics of
DD development, namely ﬁbroblast proliferation and palmar fascia
contraction by myoﬁbroblasts. Based on our ﬁndings, we hypothesize
that downregulated IGFBP6 expression and upregulated IGF2 expres-
sion jointly contribute to DD progression by promoting ﬁbroblast pro-
liferation, contractility and palmar fascia contraction in DD (Fig. 6).
As IGFBP-6 is a high afﬁnity IGF-II binding protein [23], we hy-
pothesized that attenuation of IGFBP6 expression and IGFBP-6 protein
levels in DD would enhance IGF-II availability and signaling. IGF-II
signaling can promote mitogenesis [45–48] and inhibit apoptosis
[49,50], and IGFBP-6 can antagonize these effects by sequesteringand inhibiting IGF-II signaling [30,51–53]. However, co-treatment
with equimolar IGFBP-6 and IGF-II elicited similar negative effects
on the net proliferation compared to cells treated with IGFBP-6
alone. Consistent with these ﬁndings, an IGFBP-6 analog with attenu-
ated IGF-II binding capacity (mIGFBP-6) exhibited similar effects on
PF cell proliferation relative to native IGFBP-6. These data suggest
that IGFBP-6 inhibits PF cell proliferation through mechanisms that
are independent of IGF-II sequestration, consistent with a subset of
reports of IGFBP-6 actions in other diseases [31,54,55]. In contrast to
PF and CT cells, mIGFBP-6 was signiﬁcantly less effective at inhibiting
the DD cell proliferation than native IGFBP-6. IGF2 expression is en-
hanced in DD cells relative to PF and CT cells, and exogenous IGF-II
treatment did not promote DD cell proliferation (Fig. 3B). We specu-
late that increased endogenous IGF-II expression in DD may be one of
the (potentially several) factors that enhance DD cell survival (rather
than proliferation) in a low IGFBP-6 environment. The identiﬁcation
and elucidation of the IGF-II dependent and independent mecha-
nisms activated by IGFBP-6 in DD cells will be a focus of future
studies.
In contrast to its inhibitory effects on cellular proliferation,
IGFBP-6 treatment did not signiﬁcantly inhibit cellular contractility.
However, IGFBP-6 was effective at attenuating the increase in PF
and DD cell contractility induced by IGF-II treatment (Fig. 5A). Over-
all, our data imply two distinct consequences of IGFBP-6 depletion in
DD that are likely to enhance disease progression; the attenuation of
IGF-II dependent and/or independent processes that increase the net
proliferation of palmar fascia cells, and the enhancement of IGF-II
induced cellular contractility.
The increased TGF-β1 expression and sensitivity and enhanced
basal contractility of DD cells [39–41] suggest that DD cells have dif-
ferentiated further toward a myoﬁbroblast phenotype than PF cells.
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Fig. 3. IGFBP-6 inhibits the proliferation of DD, PF and CT cells. Net proliferation (growth and/or apoptosis) of CT (white bars, N = 3 patients), PF (grey bars, N = 4 patients) and DD
(black bars, N = 4 patients) cells cultured on type-I collagen substrates was assessed using the WST-1 assay. Data are shown as change scores (cell numbers on day 7 minus cell
numbers on day 1). Signiﬁcant effects of treatment vs vehicle are indicated as * p b 0.05 and ** p b 0.01. Treatments were the following: A) IGFBP-6 treatment (400 ng/ml)
vs vehicle, B) IGF-II treatment (100 ng/ml) vs vehicle, C) IGF-II + IGFBP-6 treatment (100 ng/ml and 400 ng/ml respectively) vs vehicle, and D) mIGFBP-6 (400 ng/ml) or
IGFBP-6 (400 ng/ml) vs vehicle.
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some interesting, divergent behaviors in these genetically matched
cells at differing stages of differentiation. TGF-β1 treatment signiﬁ-
cantly enhanced DD cell contractility (p b 0.01) but no signiﬁcant
treatment/time interactions were evident, suggesting that the pro-
contractile effects of TGF-β1 treatment were induced prior to, and
not after, lattice release. In contrast, no signiﬁcant TGF-β1 treatment
effects on PF cells were detected, and a signiﬁcant (p b 0.01) time/
treatment interaction was evident, suggesting that most of the con-
tractility induced by TGF-β1 in PF cells occurred during the lattice
contraction phase after release. These differences are visually evident
in the parallel versus divergent contraction curves in Fig. 4C and D. In
contrast, IGF-II induced treatment and treatment/time interactions in
DD cells, indicating effects of treatment both pre- and post-release.
IGF-II also induced treatment and treatment/time interactions in PF
cells, however simple main effects analyses revealed that IGF-II treat-
ment did not signiﬁcantly affect lattice contraction until 2 h after re-
lease. These data suggest that IGF-II can act both pre- and post-release
to enhance DD contraction, while acting mostly post-release to
increase PF cell contraction. Thus, IGF-II and TGF-β1 may activate dis-
tinct pro-contractile signaling pathways in DD and PF cells. Despite
the potential for IGF-II and TGF-β1 to induce cellular contraction
through different signaling pathways, we were unable to detect
signiﬁcant additive effects of TGF-β1 and IGF-II treatment in our anal-
yses. The molecular mechanisms activated by IGF-II to enhance the
contractility of DD and PF cells are currently unclear.
Consistent with their contractile myoﬁbroblast-like phenotype,
untreated DD cells contracted rFPCLs to a greater extent than PFcells over 24 h. DD cell contraction of rFPCLs was signiﬁcantly
(p b 0.05) enhanced by IGF-II, whereas PF cells were insensitive to
IGF-II treatment under identical conditions. These data suggest that
IGF-II can induce lattice contraction by DD cells without modifying
the differentiation state of these cells, a process that typically requires
a 48–72 h pre-incubation period under isometric tension. We specu-
late that IGF-II enhances the three-dimensional migration of DD cells
in these rFPCLs, an effect previously shown for normal ﬁbroblasts
treated with PDGF [33]. PDGF treatment signiﬁcantly enhanced
rFPCL contraction by both DD (p b 0.01) and PF (p b 0.05) cells
(Fig. 4A), whereas TGF-β1, which signiﬁcantly enhanced DD cell con-
traction in sFPCLs (Fig. 4B), had no discernible effects on the contrac-
tility of DD or PF cells in rFPCLs (data not shown). That IGF-II
enhanced rFPCL contraction by DD cells but not PF cells suggests
that DD cells have enhanced sensitivity to IGF-II signaling, and that
there may be a functional link between IGF-II sensitivity and the dif-
ferentiation state of these cells. If future studies are able to substanti-
ate this link, local administration of IGF signaling inhibitors [56–58]
may have utility as novel treatment approaches to attenuate the con-
tractility of myoﬁbroblasts in DD patients post surgery. Alternatively,
novel therapies that restore IGFBP-6 levels to those evident in normal
palmar fascia may be sufﬁcient to attenuate IGF-II signaling and
myoﬁbroblast contractility.
5. Conclusion
These novel ﬁndings support our hypothesis that the attenuation
of IGFBP6 expression and enhancement of IGF2 expression promote
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Fig. 4. IGF-II enhances DD cell contraction of collagen lattices. The effects of IGF-II on PF (grey bars) and DD (black bars) cell contractility were assessed in relaxed ﬁbroblast pop-
ulated collagen lattice assays (rFPCLs) over 24 h (A) and stressed FPCLs (sFPCLs) over 6 h (B, C and D) as described in the Methods section. Signiﬁcant treatment effects are denoted
as * p b 0.05, ** p b 0.01 and *** p b 0.001. The effects of treatment vs vehicle on rFPCL contraction were assessed by t-test analyses at 24 h (N = 4 patients). The effects of treat-
ment vs vehicle on sFPCL contraction were assessed by ANOVA of repeated measures analyses and, where treatment/time interactions were detected, by simple main effects anal-
yses (N = 10 patients). Treatments were the following: A) IGF-II (100 ng/ml) or PDGF (100 ng/ml) in rFPCLs and B) IGF-II (100 ng/ml) or TGF-β1 (12.5 ng/ml) in sFPCLs.
C) Contraction curves for PF cells from 0.5 h to 6 h after lattice release with vehicle, TGF-β1 or IGF-II treatment. D) Contraction curves for DD cells from 0.5 h to 6 h after lattice
release with vehicle, TGF-β1 or IGF-II treatment. Signiﬁcant treatment/time interactions are denoted as * p b 0.05 and ** p b 0.01.
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nous IGF-II potently enhanced the contractility of DD cells. Future
studies will focus on elucidating the IGF-II-independent mechanisms
regulated by IGFBP-6, and the mechanisms by which IGF-II signalingPF DD
*
***
A
IGFBP-6     - - +           - - +   
IGF-II          - +          +           - +           +
T
I
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Fig. 6. Downregulated IGFBP-6 and upregulated IGF-II levels contribute to DD progres-
sion. We hypothesize that the differing IGFBP-6 and IGF-II levels evident between cells
derived from “latent disease” tissues (PF cells) and diseased tissues (DD cells) reﬂect the
roles played by these factors in promoting DD development. Downregulation of IGFBP-6
promotes cellular proliferation through IGF-II dependent and IGF-II independent mecha-
nisms. In parallel, the upregulation of IGF-II signaling enhances cellular contractility
through mechanisms that may be distinct from those induced by TGF-β1.
1518 C. Raykha et al. / Biochimica et Biophysica Acta 1832 (2013) 1511–1519Author contributions
CR and JC conducted the in vitro studies. BSG provided the primary
surgical isolates from which primary cells were derived by CR and JC
and contributed conceptually to the project. PF and LAB supplied the
mutant IGFBP-6 and contributed conceptually to the project. DBO
originally conceived of the project and coordinated all experimental
approaches. CR, JC, BSG, LAB and DBO contributed to the drafting of
the ﬁnal manuscript.Acknowledgements
The authors would like to acknowledge the Hand and Upper Limb
Centre, the Lawson Health Research Institute Internal Research Fund,
the University of Western Ontario Academic Development Fund, the
Plastic Surgery Foundation, the National Health and Medical Research
Council of Australia and the Canadian Institutes of Health Research for
their funding support.References
[1] A.P. Saboeiro, J.J. Porkorny, S.I. Shehadi, K.S. Virgo, F.E. Johnson, Racial distribution
of Dupuytren's disease in Department of Veterans Affairs patients, Plast. Reconstr.
Surg. 106 (2000) 71–75.
[2] J.D. Saar, P.C. Grothaus, Dupuytren's disease: an overview, Plast. Reconstr. Surg.
106 (2000) 125–134, (quiz 135-126).
[3] K.G. Gudmundsson, R. Arngrimsson, N. Sigfusson, A. Bjornsson, T. Jonsson, Epide-
miology of Dupuytren's disease: clinical, serological, and social assessment. The
Reykjavik study, J. Clin. Epidemiol. 53 (2000) 291–296.
[4] S. Hindocha, S. John, J.K. Stanley, S.J. Watson, A. Bayat, The heritability of
Dupuytren's disease: familial aggregation and its clinical signiﬁcance, J. Hand.
Surg. [Am.] 31 (2006) 204–210.
[5] G. Dupuytren, Permanent retraction of the ﬁngers, produced by an affection of the
palmar fascia, Lancet 2 (1834) 222–225.
[6] D. Elliot, The early history of Dupuytren's disease, Hand Clin. 15 (1999) 1–19, (v).
[7] S. Hindocha, J.K. Stanley, S. Watson, A. Bayat, Dupuytren's diathesis revisited:
evaluation of prognostic indicators for risk of disease recurrence, J. Hand. Surg.
[Am.] 31 (2006) 1626–1634.
[8] M.E. Jabaley, Surgical treatment of Dupuytren's disease, Hand Clin. 15 (1999) 109–126,
(vii).
[9] P.A. Mullins, Postsurgical rehabilitation of Dupuytren's disease, Hand Clin. 15
(1999) 167–174, (viii).
[10] K.G. Gudmundsson, R. Arngrimsson, T. Jonsson, Eighteen years follow-up study of the
clinical manifestations and progression of Dupuytren's disease, Scand. J. Rheumatol.
30 (2001) 31–34.
[11] S. Wilbrand, A. Ekbom, B. Gerdin, Cancer incidence in patients treated surgically
for Dupuytren's contracture, J. Hand Surg. (Br.) 25 (2000) 283–287.
[12] S. Wilbrand, A. Ekbom, B. Gerdin, Dupuytren's contracture and sarcoma, J. Hand
Surg. (Br.) 27 (2002) 50–52.
[13] S. Kaur, M. Forsman, J. Ryhanen, S. Knuutila, M.L. Larramendy, No gene copy
number changes in Dupuytren's contracture by array comparative genomic
hybridization, Cancer Genet. Cytogenet. 183 (2008) 6–8.
[14] G.H. Dolmans, P.M.Werker, H.C. Hennies, D. Furniss, E.A. Festen, L. Franke, K. Becker,
P. van der Vlies, B.H.Wolffenbuttel, S. Tinschert, M.R. Toliat, M. Nothnagel, A. Franke,
N. Klopp, H.E. Wichmann, P. Nurnberg, H. Giele, R.A. Ophoff, C. Wijmenga, Wnt sig-
naling and Dupuytren's disease, N. Engl. J. Med. (2011).
[15] L. Satish, W.A. LaFramboise, S. Johnson, L. Vi, A. Njarlangattil, C. Raykha, J.M.
Krill-Burger, P.H. Gallo, D.B. O'Gorman, B.S. Gan, M.E. Baratz, G.D. Ehrlich, S.
Kathju, Fibroblasts from phenotypically normal palmar fascia exhibit molecular
proﬁles highly similar to ﬁbroblasts from active disease in Dupuytren's contracture,
BMC Med. Genomics 5 (2012) 15.[16] L. Satish, W.A. Laframboise, D.B. O'Gorman, S. Johnson, B. Janto, B.S. Gan, M.E.
Baratz, F.Z. Hu, J.C. Post, G.D. Ehrlich, S. Kathju, Identiﬁcation of differentially
expressed genes in ﬁbroblasts derived from patients with Dupuytren's contracture,
BMC Med. Genomics 1 (2008) 10.
[17] A. Qian, R.A. Meals, J. Rajfer, N.F. Gonzalez-Cadavid, Comparison of gene expres-
sion proﬁles between Peyronie's disease and Dupuytren's contracture, Urology
64 (2004) 399–404.
[18] L.C. Lee, A.Y. Zhang, A.K. Chong, H. Pham, M.T. Longaker, J. Chang, Expression of a
novel gene, MafB, in Dupuytren's disease, J. Hand. Surg. [Am.] 31 (2006) 211–218.
[19] S. Rehman, F. Salway, J.K. Stanley, W.E. Ollier, P. Day, A. Bayat, Molecular pheno-
typic descriptors of Dupuytren's disease deﬁned using informatics analysis of the
transcriptome, J. Hand. Surg. [Am.] 33 (2008) 359–372.
[20] B. Shih, D. Wijeratne, D.J. Armstrong, T. Lindau, P. Day, A. Bayat, Identiﬁcation of
biomarkers in Dupuytren's disease by comparative analysis of ﬁbroblasts versus tis-
sue biopsies in disease-speciﬁc phenotypes, J. Hand. Surg. [Am.] 34 (2009) 124–136.
[21] L. Vi, L. Feng, R.D. Zhu, Y. Wu, L. Satish, B.S. Gan, D.B. O'Gorman, Periostin differ-
entially induces proliferation, contraction and apoptosis of primary Dupuytren's
disease and adjacent palmar fascia cells, Exp. Cell Res. (2009).
[22] R.C. Baxter, Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs
and intrinsic bioactivities, Am. J. Physiol. Endocrinol. Metab. 278 (2000) E967–E976.
[23] L.A. Bach, IGFBP-6 ﬁve years on; not so ‘forgotten’? Growth Hormon. IGF Res. 15
(2005) 185–192.
[24] L.A. Bach, Insulin-like growth factor binding protein-6: the “forgotten” binding
protein? Horm. Metab. Res. 31 (1999) 226–234.
[25] J.C. Howard, V.M. Varallo, D.C. Ross, J.H. Roth, K.J. Faber, B. Alman, B.S. Gan, Elevat-
ed levels of beta-catenin and ﬁbronectin in three-dimensional collagen cultures
of Dupuytren's disease cells are regulated by tension in vitro, BMC Musculoskelet.
Disord. 4 (2003) 16.
[26] E. Bell, B. Ivarsson, C. Merrill, Production of a tissue-like structure by contraction
of collagen lattices by human ﬁbroblasts of different proliferative potential in
vitro, Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 1274–1278.
[27] J. Tomasek, G.M. Rayan, Correlation of alpha-smooth muscle actin expression and
contraction inDupuytren's diseaseﬁbroblasts, J. Hand Surg. [Am] 20 (1995) 450–455.
[28] J.C. Dallon, H.P. Ehrlich, A review of ﬁbroblast-populated collagen lattices, Wound
Repair Regen. 16 (2008) 472–479.
[29] A.G. Marks, J.M. Carroll, J.Q. Purnell, C.T. Roberts Jr., Plasma distribution and
signaling activities of IGF-II precursors, Endocrinology 152 (2011) 922–930.
[30] S.L. Leng, K.S. Leeding, R.H. Whitehead, L.A. Bach, Insulin-like growth factor
(IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhe-
sion of LIM 1215 colon cancer cells, Mol. Cell. Endocrinol. 174 (2001) 121–127.
[31] P. Fu, J.A. Thompson, L.A. Bach, Promotion of cancer cell migration: an insulin-like
growth factor (IGF)-independent action of IGF-binding protein-6, J. Biol. Chem.
282 (2007) 22298–22306.
[32] F. Grinnell, Fibroblast mechanics in three-dimensional collagen matrices, J. Bodyw.
Mov. Ther. 12 (2008) 191–193.
[33] H. Jiang, S. Rhee, C.H. Ho, F. Grinnell, Distinguishing ﬁbroblast promigratory and
procontractile growth factor environments in 3-D collagen matrices, FASEB J. 22
(2008) 2151–2160.
[34] S. Rhee, F. Grinnell, Fibroblast mechanics in 3D collagen matrices, Adv. Drug Deliv.
Rev. 59 (2007) 1299–1305.
[35] H.P. Ehrlich, The modulation of contraction of ﬁbroblast populated collagen
lattices by types I, II, and III collagen, Tissue Cell 20 (1988) 47–50.
[36] R. Tse, J. Howard, Y. Wu, B.S. Gan, Enhanced Dupuytren's disease ﬁbroblast popu-
lated collagen lattice contraction is independent of endogenous active TGF-beta2,
BMC Musculoskelet. Disord. 5 (2004) 41.
[37] M.B. Vaughan, E.W. Howard, J.J. Tomasek, Transforming growth factor-beta1
promotes the morphological and functional differentiation of the myoﬁbroblast,
Exp. Cell Res. 257 (2000) 180–189.
[38] G.R. Grotendorst, H. Rahmanie, M.R. Duncan, Combinatorial signaling pathways
determine ﬁbroblast proliferation and myoﬁbroblast differentiation, FASEB J. 18
(2004) 469–479.
[39] M.A. Badalamente, S.P. Sampson, L.C. Hurst, A. Dowd, K. Miyasaka, The role of
transforming growth factor beta in Dupuytren's disease, J. Hand. Surg. [Am.] 21
(1996) 210–215.
[40] R.J. Alioto, R.N. Rosier, R.I. Burton, J.E. Puzas, Comparative effects of growth factors
on ﬁbroblasts of Dupuytren's tissue and normal palmar fascia, J. Hand. Surg. [Am.]
19 (1994) 442–452.
[41] M.A. Bisson, D.A. McGrouther, V. Mudera, A.O. Grobbelaar, The different charac-
teristics of Dupuytren's disease ﬁbroblasts derived from either nodule or cord:
expression of alpha-smooth muscle actin and the response to stimulation by
TGF-beta1, J. Hand Surg. (Br.) 28 (2003) 351–356.
[42] P.J. Wipff, B. Hinz, Myoﬁbroblasts work best under stress, J. Bodyw. Mov. Ther. 13
(2009) 121–127.
[43] B. Hinz, Tissue stiffness, latent TGF-beta1 activation, and mechanical signal
transduction: implications for the pathogenesis and treatment of ﬁbrosis, Curr.
Rheumatol. Rep. 11 (2009) 120–126.
[44] P.J. Wipff, D.B. Rifkin, J.J. Meister, B. Hinz, Myoﬁbroblast contraction activates
latent TGF-beta1 from the extracellular matrix, J. Cell Biol. 179 (2007) 1311–1323.
[45] P. Scalia, E. Heart, L. Comai, R. Vigneri, C.K. Sung, Regulation of the Akt/Glycogen
synthase kinase-3 axis by insulin-like growth factor-II via activation of the human
insulin receptor isoform-A, J. Cell. Biochem. 82 (2001) 610–618.
[46] K.J. Rolfe, A.D. Cambrey, J. Richardson, L.M. Irvine, A.O. Grobbelaar, C. Linge,
Dermal ﬁbroblasts derived from fetal and postnatal humans exhibit distinct
responses to insulin like growth factors, BMC Dev. Biol. 7 (2007) 124.
[47] H. Yoo, S.J. Kim, Y. Kim, H. Lee, T.Y. Kim, Insulin-like growth factor-II regulates the
12-lipoxygenase gene expression and promotes cell proliferation in human
1519C. Raykha et al. / Biochimica et Biophysica Acta 1832 (2013) 1511–1519keratinocytes via the extracellular regulatory kinase and phosphatidylinositol
3-kinase pathways, Int. J. Biochem. Cell Biol. 39 (2007) 1248–1259.
[48] F. Frasca, G. Pandini, P. Scalia, L. Sciacca, R. Mineo, A. Costantino, I.D. Goldﬁne, A.
Belﬁore, R. Vigneri, Insulin receptor isoform A, a newly recognized, high-afﬁnity
insulin-like growth factor II receptor in fetal and cancer cells, Mol. Cell. Biol. 19
(1999) 3278–3288.
[49] K.A. Longo, J.A. Kennell, M.J. Ochocinska, S.E. Ross, W.S. Wright, O.A. MacDougald,
Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction
of insulin-like growth factors, J. Biol. Chem. 277 (2002) 38239–38244.
[50] S. Kalla Singh, Q.W. Tan, C. Brito, M. De Leon, C. Garberoglio, D. De Leon, Differential
insulin-like growth factor II (IGF-II) expression: a potential role for breast cancer
survival disparity, Growth Hormon. IGF Res. 20 (2012) 162–170.
[51] M.A. Gallicchio, M. Kneen, C. Hall, A.M. Scott, L.A. Bach, Overexpression of
insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth
in vivo, Int. J. Cancer 94 (2001) 645–651.
[52] D. Seurin, C. Lassarre, G. Bienvenu, S. Babajko, Insulin-like growth factor binding
protein-6 inhibits neuroblastoma cell proliferation and tumour development,
Eur. J. Cancer 38 (2002) 2058–2065.
[53] E.J. Kim, B.S. Schaffer, Y.H. Kang, R.G. Macdonald, J.H. Park, Decreased production
of insulin-like growth factor-binding protein (IGFBP)-6 by transfection of coloncancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of
cell proliferation, J. Gastroenterol. Hepatol. 17 (2002) 563–570.
[54] Y.S. Kuo, Y.B. Tang, T.Y. Lu, H.C. Wu, C.T. Lin, IGFBP-6 plays a role as an
oncosuppressor gene in NPC pathogenesis through regulating EGR-1 expression,
J. Pathol. 222 (2012) 299–309.
[55] C. Iosef, G. Vilk, T. Gkourasas, K.J. Lee, B.P. Chen, P. Fu, L.A. Bach, G. Lajoie, M.B.
Gupta, S.S. Li, V.K. Han, Insulin-like growth factor binding protein-6 (IGFBP-6)
interacts with DNA-end binding protein Ku80 to regulate cell fate, Cell. Signal.
22 (2011) 1033–1043.
[56] L.R. Molife, P.C. Fong, L. Paccagnella, A.H. Reid, H.M. Shaw, L. Vidal, H.T. Arkenau,
V. Karavasilis, T.A. Yap, D. Olmos, J. Spicer, S. Postel-Vinay, D. Yin, A. Lipton, L.
Demers, K. Leitzel, A. Gualberto, J.S. de Bono, The insulin-like growth factor-I
receptor inhibitor ﬁgitumumab (CP-751,871) in combination with docetaxel in
patients with advanced solid tumours: results of a phase Ib dose-escalation,
open-label study, Br. J. Cancer 103 (2010) 332–339.
[57] A. Gualberto, Figitumumab (CP-751,871) for cancer therapy, Expert. Opin. Biol.
Ther. 10 (2010) 575–585.
[58] M. Scartozzi, M. Bianconi, E. Maccaroni, R. Giampieri, R. Berardi, S. Cascinu,
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the
treatment of cancer, Curr. Opin. Mol. Ther. 12 (2011) 361–371.
